Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Vorolanib (Primary) ; F-18 fluorothymidine
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 01 Aug 2018 Status changed from active, no longer recruiting to discontinued.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.